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ministration of adequate therapy with
greater hospital mortality [4–6]. In a study
of SAB, Lodise et al [7] found that delayed
treatment was an independent predictor
of infection-related mortality. Schramm et
al [8] examined 549 patients with sterile
site infections due to methicillin-resistant
Staphylococcus aureus (474 with SAB) and
also showed that not administering ade-
quate antibiotic therapy within 24 h of
developing infection increased the risk of
hospital mortality, by both univariate and
multivariate analyses.
Although, the current study of SAB
failed to demonstrate an association be-
tween adequate therapy and outcome,
physicians should be careful not to min-
imize the clinical importance of getting
antibiotic therapy “right” as soon as pos-
sible. This would appear to be most im-
portant for the sickest patients, including
those with septic shock and neutropenia
[9, 10]. Therefore, it seems logical to de-
velop local strategies aimed at optimizing
treatment practices for patients with se-
rious infections, including SAB. Such
strategies should include the administra-
tion of adequate antibiotic therapy ad-
ministered in a timely manner.
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To the Editor.—Dr. Kollef [1] raises a
concern related to the definition of ade-
quate therapy as used in our study [2].
Patients were classified as receiving ade-
quate therapy despite treatment delays of
up to 2 days (1 day with severe sepsis and
septic shock) after the onset of Staphylo-
coccus aureus bacteremia, whereas several
investigators have demonstrated, in ret-
rospective studies, associations between
the timing of adequate antimicrobial ther-
apy and outcome.
In our study, delay of adequate anti-
microbial therapy was not associated with
increased mortality, which contradicts
with some [3–6] but not all studies [7–9].
Data on hour of prescription were lacking
in our database; however, the association
between inadequate therapy and mortality
was not stronger when taking 1 day as the
cutoff for all cases of bacteremia.
The obvious intuitive association be-
tween inadequate treatment and mortality
may be obscured by several factors. First,
the definitions of inadequate therapy are
inherently arbitrary and vary among stud-
ies [10, 11]. We used the recommenda-
tions provided by McGregor et al [10] to
define appropriate treatment as validly as
possible.
Second, because such studies are ob-
servational, removing confounding factors
is a challenge. In observational studies, sig-
nificant differences that exist between
treatment groups may not be adjusted suf-
ficiently using commonly used multivar-
iable techniques. As an example, we con-
sider a study of critically ill patients with
bacteremia, in which therapy was defined
as inadequate if administered antimicro-
bials were ineffective against the causative
pathogen at the time of identification of
the microorganism and its antibiotic sus-
ceptibility [12]. The estimated “adjusted”
effect of inadequate antimicrobial treat-
ment of bloodstream infection, compared
to adequate therapy, on hospital mortality
had an odds ratio of 6.9, after including
the following factors: use of vasopressors,
age, organ dysfunction, and severity of ill-
ness, in a multivariable logistic regression
model.
A major limitation of such an analysis
is that the model only includes confound-
ers based on statistical significance with
respect to mortality (determined by a step-
wise variable selection approach, with a P
value of .05 as the limit for acceptance or
removal of terms), which may inappro-
priately exclude important confounding
factors that adjust for differences between
treatment groups, such as time in the hos-
pital prior to bloodstream infection, prior
use of antimicrobials, and serum albumin
level. Presumably, these differences were
factors that influenced the probability that
treatment was inadequate, or they were
proxies for such factors. Not including
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these factors in the model may contribute
to an exaggerated estimate of an effect
[12]. Therefore, we added a propensity
score as an additional covariate to deter-
mine whether measured differences be-
tween the inadequate and adequate treat-
ment groups contributed to residual con-
founding [7, 11].
Third, outcome depends on the pop-
ulation studied. Several studies have high-
lighted specific populations with bactere-
mia that may be vulnerable to inappro-
priate antimicrobial therapy: patients in
intensive care units [12], patients with sep-
tic shock [13], patients with nosocomial
bacteremia [5], or patients with neutro-
penia [7]. In contrast, studies that in-
cluded more heterogeneous patient pop-
ulations have found a lack of association
[9]. Our study included a heterogene-
ous patient population, including patients
with or without severe sepsis, patients
with methicillin-susceptible S. aureus
bacteremia, patients with methicillin-re-
sistant S. aureus bacteremia, and patients
with community-acquired or hospital-
acquired primary and secondary bacte-
remia. The study was underpowered to
detect an association between antimicro-
bial therapy and mortality within specific
subgroups of patients with bacteremia.
Fourth, many studies only report sin-
gle-center results, often from US tertiary
care centers [5, 6], in contrast to our study,
which reported the results of 60 randomly
selected teaching and nonteaching hos-
pitals in Europe. Finally, outcome depends
on the microorganism studied. Mortality
associated with gram-negative bacteremia
or candidemia cannot be compared with
S. aureus bacteremia [14].
Yet, as explicitly stated in our study, we
are not advocating that physicians stop re-
lying on the importance of immediate ad-
ministration of appropriate antimicrobial
therapy for patients with potentially life-
threatening infections. On the other hand,
in a setting with a low prevalence of meth-
icillin-resistant S. aureus bacteremia, it
may be justified not to switch from em-
pirical b-lactam therapy to vancomycin in
a clinically stable patient who is not having
severe sepsis or septic shock if the micro-
biology laboratory reports gram-positive
cocci in clusters in the Gram stain of a
positive blood culture. Our findings sug-
gest that the view on what is usually con-
sidered appropriate or inappropriate ther-
apy may not be fully correct, as elegantly
stated in the accompanying editorial [15].
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To the Editor—A 25-year-old pregnant
woman (26 weeks gestation) was referred
from a private hospital in August 2009
because of severe hypoxia secondary to in-
fluenza A (H1N1) pneumonia proven by
reverse-transcription polymerase chain re-
action test. Her symptoms commenced
with one week of fever, followed by intense
cough and dyspnea requiring mechanical
ventilation. Chest radiograph showed bi-
lateral alveolar opacification involving
three-fourths of the entire lung fields. Oral
oseltamivir, nebulized zanamivir, and in-
travenous dexamethasone were initiated
promptly. The patient was ventilated by
Nellcor-Puritan-Bennett-840 ventilator in
pressure-controlled mode. At the best pos-
itive end–expiratory pressure (PEEP) of 14
cm H2O, the plateau pressure was 27 cm
H2O and the arterial oxygen partial pres-
sure–to–fraction of inspired oxygen con-
centration ratio (PaO2/FiO2) was 64. On
the second day, we observed inexplicably
low exhaled tidal volumes. Replacement
of the ventilator, under the same settings,
immediately recovered an additional 100
ml of exhaled tidal volume. The patient
was in stable condition afterward with a
pulse oxygen saturation (SpO2) of 88%–
92% until midnight of the fourth hospital
day, when the on-call physician was no-
tified of a sudden ventilator malfunction.
The nurse in charge stated that the inci-
dent happened while nebulizing zanamivir
and was preceded by a few alarms that
needed machine reset. While the patient
was waiting for a new (third) ventilator,
her SpO2 dropped to 65%. This SpO2,
however, rose slowly and reached 90% in
24 hours. At this circumstance, blockade
in the expiratory filter was suspected. To
prevent damage to the reusable filter,
we placed a disposable filter (CareStar,
Dra¨gerMedical) at the point proximal to
the main filter. At midnight of the fifth
hospital day, the problem recurred. This
time, rapid removal of the disposable filter
led to immediate resumption of ventilator
function. Examination of the removed fil-
ter demonstrated inside-blockade caused
by sticky material. Following this second
episode of ventilator malfunction, patient
became severely hypoxemic (SpO2, 71%–
78%) and developed bilateral pneumo-
thoraces. Despite all aggressive measures,
her oxygenation failed to improve and the
patient expired on the eighth hospital day.
Diagnosis and treatment of influenza A
(H1N1) pneumonia in this patient was
late, which resulted in severe acute res-
piratory distress syndrome. Because sed-
atives and muscle relaxants routinely used
in managing critical patients might cause
impaired gastrointestinal function, the ab-
sorption of oral oseltamivir becomes un-
predictable. Alternative administration of
inhaled zanamivir, although safe and ef-
fective [1, 2], is also a practical problem
in intubated patients. Endotracheal neb-
ulization of zanamivir at double doses (20
mg in saline) is therefore widely practiced
in Thailand during this influenza pan-
demic. We suspect that this incident of
filter blockade was caused by the 20 mg
lactose in each blister of zanamivir [3]. A
simulation was performed by connecting
the ventilator to a test lung and a pressure
manometer. From the sixth dose of zan-
amivir nebulization, we observed signifi-
cant retardation of expiratory flow with
1.5–2 cm H2O elevation of PEEP and air-
way pressure. Severe ventilator occlusion
occurred transiently during the eighth
dose and became persistent at the ninth
dose of nebulization—during which the
ventilator automatically opened its safety
valve and switched to a low respiratory
rate, a low airway pressure, and a zero
PEEP ventilation. Further ventilator reset
failed to recover its previous function. We
conclude that expiratory filter obstruction
caused by nebulized zanamivir resulted in
severe hypoxemia and pneumothoraces
that led to fatality in this patient. The fatal
respiratory events were immediately re-
ported to GlaxoSmithKline, and steps
were taken by GlaxoSmithKline and the
United States Food and Drug Adminis-
tration, with subsequent notification to
healthcare professionals and hospital risk
managers [4].
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